SI3204494T1 - Izboljšane metode za neaktivacijo poliovirusa, adjuvans adsorpcije - Google Patents

Izboljšane metode za neaktivacijo poliovirusa, adjuvans adsorpcije

Info

Publication number
SI3204494T1
SI3204494T1 SI201531223T SI201531223T SI3204494T1 SI 3204494 T1 SI3204494 T1 SI 3204494T1 SI 201531223 T SI201531223 T SI 201531223T SI 201531223 T SI201531223 T SI 201531223T SI 3204494 T1 SI3204494 T1 SI 3204494T1
Authority
SI
Slovenia
Prior art keywords
improved methods
adjuvant adsorption
poliovirus
inactivation
poliovirus inactivation
Prior art date
Application number
SI201531223T
Other languages
English (en)
Inventor
Rajeev Mhalasakant Dhere
Sambhaji Shankar Pisal
Jagdish Kamalaji Zade
Rajendra Narayan Sabale
Original Assignee
Serum Institute Of India Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute Of India Private Limited filed Critical Serum Institute Of India Private Limited
Publication of SI3204494T1 publication Critical patent/SI3204494T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/125Picornaviridae, e.g. calicivirus
    • A61K39/13Poliovirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • C12N7/045Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • C12N7/06Inactivation or attenuation by chemical treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32311Enterovirus
    • C12N2770/32334Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32611Poliovirus
    • C12N2770/32634Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32611Poliovirus
    • C12N2770/32661Methods of inactivation or attenuation
    • C12N2770/32663Methods of inactivation or attenuation by chemical treatment
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32611Poliovirus
    • C12N2770/32671Demonstrated in vivo effect
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI201531223T 2014-10-07 2015-10-06 Izboljšane metode za neaktivacijo poliovirusa, adjuvans adsorpcije SI3204494T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3180MU2014 2014-10-07
EP15831237.1A EP3204494B1 (en) 2014-10-07 2015-10-06 Improved methods for poliovirus inactivation, adjuvant adsorption
PCT/IN2015/000376 WO2016063291A1 (en) 2014-10-07 2015-10-06 Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof

Publications (1)

Publication Number Publication Date
SI3204494T1 true SI3204494T1 (sl) 2020-08-31

Family

ID=55300742

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201531223T SI3204494T1 (sl) 2014-10-07 2015-10-06 Izboljšane metode za neaktivacijo poliovirusa, adjuvans adsorpcije

Country Status (24)

Country Link
US (1) US10485862B2 (sl)
EP (2) EP3204494B1 (sl)
JP (2) JP6755243B2 (sl)
KR (2) KR102219638B1 (sl)
CN (2) CN113368227A (sl)
AU (2) AU2015334495B2 (sl)
BR (1) BR112017007089A2 (sl)
CA (1) CA2963897C (sl)
CU (1) CU24510B1 (sl)
CY (1) CY1123078T1 (sl)
DK (1) DK3204494T3 (sl)
EA (1) EA201700187A1 (sl)
ES (1) ES2803578T3 (sl)
HU (1) HUE049104T2 (sl)
LT (1) LT3204494T (sl)
MX (1) MX2017004534A (sl)
PE (1) PE20171132A1 (sl)
PH (1) PH12017500627A1 (sl)
PL (1) PL3204494T3 (sl)
PT (1) PT3204494T (sl)
SG (2) SG10202010814RA (sl)
SI (1) SI3204494T1 (sl)
UA (1) UA125788C2 (sl)
WO (1) WO2016063291A1 (sl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6755243B2 (ja) * 2014-10-07 2020-09-16 セラム インスティチュート オブ インディア プライベイト リミテッド エンテロウイルス不活化およびアジュバント吸着のための改良された方法、ならびに、それから得られる投与量減量ワクチン組成物
EP3454895B1 (en) * 2016-05-10 2024-03-27 Najit Technologies, Inc. Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production
EP3503917B1 (en) * 2016-08-26 2024-07-03 Serum Institute Of India Private Limited Multivalent vaccine composition
TWI711700B (zh) * 2017-07-10 2020-12-01 印度商印度血清研究公司 使腸病毒去活化之改良方法、佐劑吸附及所獲得之劑量減少的疫苗組成物
MX2020004543A (es) 2017-11-03 2020-09-18 Takeda Vaccines Inc Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
MX2020004633A (es) 2017-11-30 2020-09-28 Takeda Vaccines Inc Metodo para inactivar el virus de zika y metodos relacionados.
WO2019155492A1 (en) * 2018-02-07 2019-08-15 Bharat Biotech International Limited A process for enterovirus purification and inactivation and vaccine compositions obtained thereof
CN109550046B (zh) * 2018-12-21 2020-08-25 北京民海生物科技有限公司 一种吸附无细胞百白破-脊髓灰质炎-b型流感嗜血杆菌联合疫苗及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1762246A1 (en) * 1996-07-02 2007-03-14 Sanofi Pasteur Limited Multivalent DTP-Polio vaccines
EP1793852A1 (en) * 2004-08-27 2007-06-13 Panacea Biotec Ltd. Inactivated poliomyelitis vaccine derived from sabin strain of polio virus
CN1647822A (zh) * 2005-02-06 2005-08-03 北京生物制品研究所 脊髓灰质炎灭活疫苗及其制备方法
AU2007293673B2 (en) 2006-09-07 2013-06-27 Glaxosmithkline Biologicals S.A. Vaccine
CN100540662C (zh) * 2006-12-06 2009-09-16 云南沃森生物技术有限公司 一种混合床凝胶过滤层析技术用于病毒性疫苗纯化的方法
WO2010036226A1 (en) * 2008-09-26 2010-04-01 George Nelson Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis
CN102655879B (zh) * 2009-12-16 2016-03-09 印度血清研究所 疫苗组合物
EP2680885B8 (en) * 2011-03-02 2018-07-25 GlaxoSmithKline Biologicals SA Combination vaccines with lower doses of antigen and/or adjuvant
GB201105981D0 (en) * 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
JP6755243B2 (ja) 2014-10-07 2020-09-16 セラム インスティチュート オブ インディア プライベイト リミテッド エンテロウイルス不活化およびアジュバント吸着のための改良された方法、ならびに、それから得られる投与量減量ワクチン組成物

Also Published As

Publication number Publication date
JP2020203906A (ja) 2020-12-24
CA2963897C (en) 2023-08-22
ES2803578T3 (es) 2021-01-28
EP3204494A1 (en) 2017-08-16
JP6755243B2 (ja) 2020-09-16
PL3204494T3 (pl) 2020-09-21
PT3204494T (pt) 2020-07-10
MX2017004534A (es) 2017-10-11
CA2963897A1 (en) 2016-04-28
US20170348411A1 (en) 2017-12-07
KR102510744B1 (ko) 2023-03-15
KR20170063947A (ko) 2017-06-08
AU2015334495A1 (en) 2017-05-25
PH12017500627A1 (en) 2017-09-25
EP3663396A1 (en) 2020-06-10
CN113368227A (zh) 2021-09-10
WO2016063291A1 (en) 2016-04-28
EP3204494B1 (en) 2020-04-01
AU2021269395A1 (en) 2021-12-16
KR20210021148A (ko) 2021-02-24
LT3204494T (lt) 2020-07-10
AU2015334495B2 (en) 2021-08-19
JP2017533899A (ja) 2017-11-16
JP7063957B2 (ja) 2022-05-09
CY1123078T1 (el) 2021-10-29
SG11201702838SA (en) 2017-05-30
NZ731341A (en) 2023-11-24
BR112017007089A2 (pt) 2017-12-26
KR102219638B1 (ko) 2021-02-23
US10485862B2 (en) 2019-11-26
HUE049104T2 (hu) 2020-08-28
PE20171132A1 (es) 2017-08-09
CU24510B1 (es) 2021-05-12
AU2021269395B2 (en) 2024-05-23
CN106999569A (zh) 2017-08-01
UA125788C2 (uk) 2022-06-08
DK3204494T3 (da) 2020-07-06
SG10202010814RA (en) 2020-12-30
CU20170044A7 (es) 2018-09-05
CN106999569B (zh) 2021-06-29
EA201700187A1 (ru) 2017-12-29

Similar Documents

Publication Publication Date Title
IL251451A0 (en) Methods for limited direct detection
PL3183349T3 (pl) Sposób przygotowania Rebaudiozydu I
SG11201700477WA (en) Microporous carbon adsorbent from natural carbohydrates
LT3204494T (lt) Polioviruso inaktyvavimo, adjuvanto adsorpcijos pagerinti būdai
GB201413335D0 (en) Agricultural methods
PL3113797T3 (pl) Przeciwciała, zastosowania i metody
IL273265A (en) New combinations for antigen-based therapy
PL3197890T3 (pl) Dipodstawione związki diaryloksybenzoheterodiazolowe
HK1249014A1 (zh) 具有作為佐劑的cd40配體的疫苗
EP3154922A4 (en) Process for preparing dialkylbiphenyl isomer mixtures
PL3178803T3 (pl) Sposób wytwarzania 2,3,3,3-tetrafluoropropenu
PL3160984T3 (pl) Sposób wytwarzania d-arginylo-2,6-dimetylo-l-tyrozylo-l-lizylol- fenyloalaninoamidu
PL3122717T3 (pl) Eteroaminy na bazie 1,2-dialkoholi
AU358414S (en) Frame for chair
GB2522989B (en) Sorbent for halogen compounds
ZA201607068B (en) Methods for treating hypersomnia
HRP20181756T1 (hr) Režim liječenja sa spojem tiakumicina
PL2949390T3 (pl) Instalacja adsorpcyjna
GB201406755D0 (en) Indigestion, angled adjustable bed
HU4547U (en) Bed for pregnants
GB201420970D0 (en) eGURE, egure, Egure
AU2014905272A0 (en) Improved bed
GB201405427D0 (en) Disc Cultivator
GB201413337D0 (en) Agricultural methods
TWM488919U (en) Storagable bed frame